Transdermal Drug Delivery Videos

1. Clarifying The EDDO Focus On Design Outputs, Not Design Inputs 10/9/2024

   In what ways are Essential Drug Delivery Outputs (EDDOs) different from design inputs for combination products? In this segment of the Drug Delivery Leader Live event The FDA Guidance on EDDO: What to Know, What to Do, consultant Susan Neadle of Combination Products Consulting Services, LLC explains the difference.

2. Formulations, Devices, Regulations, and Patients: Two Takes On Drug Delivery Trends 3/14/2025

   In this unique episode of In Combination, series host Tom von Gunden, Chief Editor at Drug Delivery Leader, puts himself in combination with DDL Executive Editor Fran DeGrazio as the two share perspectives on drug delivery trends.

3. Developing Regulatory Strategies For Combination Products 12/16/2024

   In this episode of The Combination Products Handbook: The Series, host Tom von Gunden discusses Chapter 3 of The Combination Products Handbook: A Practical Guide for Combination Products and Other Combined Use Systems (CRC Press) with the book’s editor Susan Neadle. The conversation focuses on building into product development a regulatory strategy that incorporates key enablers of market success from early clinical studies, through the marketing application, to post-market changes.

4. Platform Approaches To Personalized Medicines With NanoVation's Dominik Witzigmann 3/20/2025

   In this episode of Supplier Horizons, host Tom von Gunden talks with CEO Dominik Witzigmann of LNP (lipid nanoparticle) platform developer NanoVation Therapeutics about addressing a wide range of patient needs while partnering with biopharma and navigating the regulatory landscape to do so.

5. The Landscape For Advanced Therapies And Combination Products 10/8/2025

   In this segment of the Drug Delivery Leader Live online event, Next-Gen Drug Delivery: Rethinking Routes For New Therapies, James Wabby, head of global regulatory affairs for emerging device technologies and combination products at AbbVie, traces key conditions driving and impacting the development of advanced therapies and combination products. These include the demand for precision medicines, the complexity of regulatory frameworks, and pressures on healthcare systems. 

6. Managing Risk When Developing Combination Products 2/20/2025

   In this episode of The Combination Products Handbook: The Series, host Tom von Gunden discusses Chapter 6 on risk management from The Combination Products Handbook: A Practical Guide for Combination Products and Other Combined Use Systems (CRC Press) with the book’s editor, Susan Neadle, and chapter co-author Edwin Bills.

7. Balancing User-Related Risk Assessments With Use-Enabling Device Enhancements 12/11/2024

   Can a diligent focus on patient safety during combination product development inadvertently lead to missed opportunities for device use enhancements? In this segment of the Drug Delivery Leader Live event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Natalie, Abts, head of human factors engineering at Genentech, discusses ways to keep the organization focused on developing quality products that enhance user adoptability while also mitigating user-related harm.

8. Setting The Strategic Direction For Advanced Therapy Products 10/8/2025

   In this segment of the Drug Delivery Leader Live online event, Next-Gen Drug Delivery: Rethinking Routes For New Therapies, James Wabby, head of global regulatory affairs for emerging device technologies and combination products at AbbVie, underscores the importance of cascading business and regulatory strategies for advanced therapies and delivery products throughout the organization’s quality management systems. 

9. Enabling In-Home Drug Delivery With SMC's Asmita Khanolkar 12/10/2024

   Methods for enabling self-administered, in-home delivery of drugs and biologics must accommodate increasingly larger volumes and more complex formulations. In this episode of Supplier Horizons, host Tom von Gunden talks with Asmita Khanolkar, Senior Director of Pharma Services at contract manufacturer SMC Ltd., about patient-centric considerations such as ergonomics and tolerability in the development of combination products, autoinjectors, and other delivery systems.

10. Rare Disease Targeting and Novel Therapy Delivery with Kymanox' Evan Edwards 8/29/2024

    Commenting on a wide range of therapeutic targets, Kymanox president Evan Edwards joins Supplier Horizons host Tom von Gunden in highlighting opportunities for drug delivery innovation. Front of mind for Evan as he considers areas of advancement are human factors engineering for increased self-administration, targeting rare diseases with novel therapies, and, in general, addressing the challenges of delivering large molecule biologics.